[Not Available].

Background: Honorary and ghost authorship, as well as competing interests, are well documented concerns related to the publication of scientific articles. Guidelines for writing and publishing scientific manuscripts are available, including those of the International Committee of Medical Journal Editors (ICMJE).

Objectives: The primary objective of this descriptive cross-sectional study was to identify, in the instructions for authors of pharmacy practice journals, guidance on authorship and competing interests.

Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.

The objective of this study was to evaluate the switch to once-daily darunavir/ritonavir 800/100 mg in treatment-experienced patients with suppressed HIV-1 replication on a twice-daily ritonavir-boosted protease-inhibitor (bid PI/r) containing regimen, that is in a setting where genotypic resistance test cannot be performed. In this open label, non-comparative, multicenter study, patients on a bid PI/r-containing triple combination, with suppressed viral replication, were switched to once-daily darunavir/r 800/100 mg containing triple combination. The primary endpoint was the proportion of patients with plasma HIV-RNA < 50 copies/ml 24 weeks after the switch.